Bristol Myers reports two-year POETYK PsA-2 results for Sotyktu
Bristol Myers Squibb announced positive through-two-years data from the Phase 3 POETYK PsA-2 study, including its open-label extension, for Sotyktu (deucravacitinib) in adults with active psoriatic arthritis.